Roger Jeffs
CIK: 0001231615
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (59 total)
- Oct 12, 2026LQDA
Liquidia Corp
Sale(S)Direct32.7K shares at avg. $28.48$933K - Oct 9, 2026LQDA
Liquidia Corp
Exercise(M)Direct13.8K shares- - Oct 9, 2026LQDA
Liquidia Corp
Exercise(M)Direct14.3K shares- - Jul 13, 2026LQDA
Liquidia Corp
Sale(S)Direct2.5K shares at avg. $71.39$179K - Jul 13, 2026LQDA
Liquidia Corp
Sale(S)Direct32.7K shares at avg. $71.52$2.3M - Jul 10, 2026LQDA
Liquidia Corp
Exercise(M)Direct14.3K shares- - Jul 10, 2026LQDA
Liquidia Corp
Exercise(M)Direct13.8K shares- - Jun 11, 2026AXSM
Axsome Therapeutics, Inc.
Sale(S)Direct286 shares at avg. $249.12$71K - Jun 10, 2026AXSM
Axsome Therapeutics, Inc.
Sale(S)Direct286 shares at avg. $246.18$70K - Jun 8, 2026AXSM
Axsome Therapeutics, Inc.
Exercise(M)Direct1.4K shares- - Jun 5, 2026AXSM
Axsome Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
1.7K shares- - May 27, 2026LQDA
Liquidia Corp
Sale(S)Indirect6.4K shares at avg. $62.18$400K - May 26, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $60.38$1.5M - May 22, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $61.52$1.5M - May 21, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $61.13$1.5M - May 20, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $61.30$1.5M - May 19, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $58.65$1.5M - May 18, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $56.77$1.4M - May 15, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $57.04$1.4M - May 14, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $58.62$1.5M - May 13, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $56.29$1.4M - May 12, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $54.04$1.4M - May 11, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $41.50$1.0M - May 8, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $42.14$1.1M - May 7, 2026LQDA
Liquidia Corp
Sale(S)Indirect25K shares at avg. $42.09$1.1M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 12, 2026 |  LQDA Liquidia Corp | Sale(S) | 32,744 | $28.48 | $932,549 | Direct |
| Oct 9, 2026 | LQDA Liquidia Corp | Exercise(M) | 13,833 | - | $0 | Direct |
| Oct 9, 2026 | LQDA Liquidia Corp | Exercise(M) | 14,333 | - | $0 | Direct |
| Jul 13, 2026 | LQDA Liquidia Corp | Sale(S) | 2,505 | $71.39 | $178,832 | Direct |
| Jul 13, 2026 | LQDA Liquidia Corp | Sale(S) | 32,744 | $71.52 | $2,341,851 | Direct |
| Jul 10, 2026 | LQDA Liquidia Corp | Exercise(M) | 14,333 | - | $0 | Direct |
| Jul 10, 2026 | LQDA Liquidia Corp | Exercise(M) | 13,834 | - | $0 | Direct |
| Jun 11, 2026 |  AXSM Axsome Therapeutics, Inc. | Sale(S) | 286 | $249.12 | $71,248 | Direct |
| Jun 10, 2026 | AXSM Axsome Therapeutics, Inc. | Sale(S) | 286 | $246.18 | $70,407 | Direct |
| Jun 8, 2026 | AXSM Axsome Therapeutics, Inc. | Exercise(M) | 1,429 | - | $0 | Direct |
| Jun 5, 2026 | AXSM Axsome Therapeutics, Inc. | Award(A) Restricted Stock Units | 1,721 | - | - | Direct |
| May 27, 2026 | LQDA Liquidia Corp | Sale(S) | 6,428 | $62.18 | $399,712 | Indirect |
| May 26, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $60.38 | $1,509,460 | Indirect |
| May 22, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $61.52 | $1,538,055 | Indirect |
| May 21, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $61.13 | $1,528,160 | Indirect |
| May 20, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $61.30 | $1,532,548 | Indirect |
| May 19, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $58.65 | $1,466,143 | Indirect |
| May 18, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $56.77 | $1,419,320 | Indirect |
| May 15, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $57.04 | $1,426,073 | Indirect |
| May 14, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $58.62 | $1,465,565 | Indirect |
| May 13, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $56.29 | $1,407,128 | Indirect |
| May 12, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $54.04 | $1,350,990 | Indirect |
| May 11, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $41.50 | $1,037,403 | Indirect |
| May 8, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $42.14 | $1,053,565 | Indirect |
| May 7, 2026 | LQDA Liquidia Corp | Sale(S) | 25,000 | $42.09 | $1,052,135 | Indirect |
1-25 of 59 transactions
About JEFFS ROGER
JEFFS ROGER (SEC CIK 0001231615) files insider reports with the SEC as Chief Executive Officer of Liquidia Corp (LQDA) and Director of Axsome Therapeutics, Inc. (AXSM).
Signal8 holds 29 ownership filings by JEFFS ROGER, all Form 4s, filed between Oct 15, 2024 and Oct 13, 2026. Those filings report 59 transactions, from Oct 14, 2024 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on JEFFS ROGER's filings is in MORRISVILLE, NC.
Recent filings by JEFFS ROGER
- Oct 12, 2026: Open-market sale of LQDA shares (Form 4, code S).
- Oct 9, 2026: Option exercises of LQDA shares (2 lines, Form 4, code M).
- Jul 13, 2026: Open-market sales of LQDA shares (2 lines, Form 4, code S).
- Jul 10, 2026: Option exercises of LQDA shares (2 lines, Form 4, code M).
- Jun 11, 2026: Open-market sale of AXSM shares (Form 4, code S).
Other insiders filing for Liquidia Corp (LQDA)
- Boyle Dana, Chief Accounting Officer
- Adair Jason, Chief Business Officer
- Schundler Russell, General Counsel
- Saggar Rajeev, Chief Medical Officer
- Moomaw Scott, Chief Commercial Officer
- Krepp Sarah, Chief Human Resource Officer